Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gert Van Assche

Showing results (101-110 of 287) with videos related to

Pageof 29
Sort By:
United European Gastroenterology Journal|December 15, 2017
Human intestinal epithelium in a dish: Current models for research into gastrointestinal pathophysiologyManuel Noben, Wiebe Vanhove, Kaline Arnauts, et al.
European Journal of Clinical Pharmacology|June 28, 2015
Pharmacokinetics of adalimumab in Crohn's diseaseDavid Ternant, Konstantinos Karmiris, Severine Vermeire, et al.
Journal of Crohn'S & Colitis|December 3, 2010
Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort studyGert Van Assche, Séverine Vermeire, Maja Noman, et al.
Journal of Crohn'S & Colitis|December 3, 2010
Rectal non-Hodgkin's lymphoma in an infliximab treated patient with ulcerative colitis and primary sclerosing cholangitisValérie Van Hauwaert, Stef Meers, Gregor Verhoef, et al.
The American Journal of Gastroenterology|August 3, 2016
A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel DiseaseThomas Billiet, Erwin Dreesen, Isabelle Cleynen, et al.
European Journal of Immunology|June 24, 2004
CXCR1-binding chemokines in inflammatory bowel diseases: down-regulated IL-8/CXCL8 production by leukocytes in Crohn's disease and selective GCP-2/CXCL6 expression in inflamed intestinal tissueKlara Gijsbers, Gert Van Assche, Sofie Joossens, et al.
Alimentary Pharmacology & Therapeutics|August 16, 2018
Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testingBram Verstockt, Gitte Moors, Sumin Bian, et al.
Gut|July 16, 2018
TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn's disease patients?Bram Verstockt, Sare Verstockt, Helene Blevi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 22, 2014
A rule for determining risk of colorectal cancer in patients with inflammatory bowel diseaseMaurice Lutgens, Séverine Vermeire, Martijn Van Oijen, et al.
Journal of Crohn'S & Colitis|December 4, 2013
Tuberculosis infection following anti-TNF therapy in inflammatory bowel disease, despite negative screeningCeline Debeuckelaere, Paul De Munter, Pascal Van Bleyenbergh, et al.
Pageof 29

Showing results (101-110 of 287) with videos related to

Sort By:
Pageof 29
United European Gastroenterology Journal|December 15, 2017
Human intestinal epithelium in a dish: Current models for research into gastrointestinal pathophysiologyManuel Noben, Wiebe Vanhove, Kaline Arnauts, et al.
European Journal of Clinical Pharmacology|June 28, 2015
Pharmacokinetics of adalimumab in Crohn's diseaseDavid Ternant, Konstantinos Karmiris, Severine Vermeire, et al.
Journal of Crohn'S & Colitis|December 3, 2010
Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort studyGert Van Assche, Séverine Vermeire, Maja Noman, et al.
Journal of Crohn'S & Colitis|December 3, 2010
Rectal non-Hodgkin's lymphoma in an infliximab treated patient with ulcerative colitis and primary sclerosing cholangitisValérie Van Hauwaert, Stef Meers, Gregor Verhoef, et al.
The American Journal of Gastroenterology|August 3, 2016
A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel DiseaseThomas Billiet, Erwin Dreesen, Isabelle Cleynen, et al.
European Journal of Immunology|June 24, 2004
CXCR1-binding chemokines in inflammatory bowel diseases: down-regulated IL-8/CXCL8 production by leukocytes in Crohn's disease and selective GCP-2/CXCL6 expression in inflamed intestinal tissueKlara Gijsbers, Gert Van Assche, Sofie Joossens, et al.
Alimentary Pharmacology & Therapeutics|August 16, 2018
Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testingBram Verstockt, Gitte Moors, Sumin Bian, et al.
Gut|July 16, 2018
TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn's disease patients?Bram Verstockt, Sare Verstockt, Helene Blevi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 22, 2014
A rule for determining risk of colorectal cancer in patients with inflammatory bowel diseaseMaurice Lutgens, Séverine Vermeire, Martijn Van Oijen, et al.
Journal of Crohn'S & Colitis|December 4, 2013
Tuberculosis infection following anti-TNF therapy in inflammatory bowel disease, despite negative screeningCeline Debeuckelaere, Paul De Munter, Pascal Van Bleyenbergh, et al.
Pageof 29